benzyl 2-oxocyclohexanecarboxylate | 2205-32-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzyl 2-oxocyclohexanecarboxylate
• 英文别名: Benzyl 2-oxocyclohexane-1-carboxylate
• CAS: 2205-32-5
• 化学式: C₁₄H₁₆O₃
• 分子量: 232.279
• InChiKey: UZOGMVJYLSQKCU-UHFFFAOYSA-N

物化性质

• 沸点：
  173-174 °C
• 密度：
  1.154±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  benzyl 2-oxocyclohexanecarboxylate 在 sodium tetrahydroborate 、 氯化亚砜 、 sodium azide 、 N,N-二甲基甲酰胺 、 异丁酸 、 肼 作用下， 以 甲醇 、 二氯甲烷 、 丙酮 、 甲苯 为溶剂， 150.0 ℃ 、5.07 MPa 条件下， 反应 69.17h， 生成 benzyl N-[(1S,2R)-2-aminocyclohexyl]carbamate
  参考文献：
  名称：

  A practical synthesis of enantiopure N-carbobenzyloxy-N′-phthaloyl-cis-1,2-cyclohexanediamine by asymmetric reductive amination and the Curtius rearrangement

  摘要：

  Enantionterically pure N-carbobenzyloxy-N'-phthaloyl-cis-1,2-cyclohexanediamine was synthesized by the asymmetric reduction of a beta-enamino ester formed from benzyl 2-oxocycloliexanecarboxylate and (R)-phenylethylamine, followed by hydrogenolysis, phthaloylation, and the Curtius rearrangement. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2007.08.014
• 作为产物：
  描述：

  dibenzyl pimelate 在 sodium hydride 作用下， 以 甲苯 为溶剂， 以71%的产率得到benzyl 2-oxocyclohexanecarboxylate
  参考文献：
  名称：

  Delineating Origins of Stereocontrol in Asymmetric Pd-Catalyzed α-Hydroxylation of 1,3-Ketoesters

  摘要：

  Systematic studies of reaction conditions and subsequent optimization led to the identification of important parameters for stereoselectivity in the asymmetric alpha-hydroxylation reaction of 1,3-ketoesters. Enantioselectivities of up to 98% can be achieved for cyclic substrates and 88% for acyclic ketoesters. Subsequently, the combination of cyclic/acyclic ketoester, catalyst, and oxidant was found to have a profound effect on reaction rates and turnover-limiting steps. The stereochemistry of the reaction contradicts that observed for other similar electrophilic substitution reactions. This was rationalized by transition-state modeling, which revealed a number of cooperative weak interactions between oxidant, ligand, and counterion, together with C-H/pi interactions that cumulatively account for the unusual stereoselectivity.

  DOI：

  10.1021/jo1002906

文献信息

• Chiral Zirconium Complex as Brønsted Base Catalyst in Asymmetric Direct-type Mannich Reactions
  作者：Shū Kobayashi、Matthew M. Salter、Yumi Yamazaki、Yasuhiro Yamashita

  DOI：10.1002/asia.200900524

  日期：2010.3.1

  Activating carbonyls: Asymmetric direct‐type Mannich reaction using a chiral zirconium complex as Brønsted base is demonstrated. Zirconium complexes prepared from Zr(OtBu) and 3,3′‐disubstituted BINOL are found to be good catalysts in the reactions of an iminoester with malonates, and high enantioselectivities are obtained.

  活化羰基：证明了使用手性锆配合物作为布朗斯台德碱的不对称直接型曼尼希反应。在亚氨基酯与丙二酸酯的反应中，发现由Zr（O t Bu）和3,3'-双取代的BINOL制备的锆络合物是良好的催化剂，并获得了高对映选择性。
• INHIBITORS OF INFLUENZA VIRUSES REPLICATION
  申请人：Charifson Paul S.

  公开号：US20120171245A1

  公开（公告）日：2012-07-05

  Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

  抑制生物样本或患者中流感病毒的复制、减少生物样本或患者中流感病毒量以及治疗患者流感的方法，包括向所述生物样本或患者施用有效量的由结构公式（I）表示的化合物： 或其药用可接受盐，其中结构公式（IA）的值如本文所述。由结构公式（IA）或其药用可接受盐表示的化合物，其中结构公式（IA）的值如本文所述。药物组合物包括有效量的上述化合物或其药用可接受盐，以及药用可接受载体、佐剂或车辆。
• Bench‐Stable <i>S</i> ‐(Monofluoromethyl)sulfonium Salts: Highly Efficient <i>C</i> ‐ and <i>O</i> ‐Regioselective Monofluoromethylation of 1,3‐Dicarbonyl Compounds
  作者：Wen‐Bing Qin、Jian‐Jian Liu、Zhongyan Huang、Xin Li、Wei Xiong、Jia‐Yi Chen、Guo‐Kai Liu

  DOI：10.1002/ejoc.202000998

  日期：2020.9.30

  Novel bench‐stable S‐(monofluoromethyl)‐S‐phenyl‐S‐(2,4,6‐trialkoxyphenyl)sulfonium salts were readily prepared for C‐ and O‐regioselective monofluoromethylation of 1,3‐dicarbonyl compounds in good to excellent yields under mild reaction conditions.

  新型稳定的S-（单氟甲基）-S-苯基-S-（2,4,6-三烷氧基苯基）ulf盐易于制备，可用于1,3-二羰基化合物的C和O区域选择性单氟甲基化在温和的反应条件下。
• [EN] INHIBITORS OF INFLUENZA VIRUSES REPLICATION<br/>[FR] INHIBITEURS DE LA RÉPLICATION DES VIRUS DE LA GRIPPE
  申请人：VERTEX PHARMA

  公开号：WO2012083117A1

  公开（公告）日：2012-06-21

  Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

  抑制流感病毒在生物样本或患者中复制的方法，减少生物样本或患者中流感病毒的数量，以及治疗患者的流感，包括向所述生物样本或患者投与结构式（I）所代表的化合物的有效量或其药学上可接受的盐，其中结构式（I）的值如本文所述。一种化合物由结构式（I）或其药学上可接受的盐所代表，其中结构式（I）的值如本文所述。一种药物组合物包括这种化合物或其药学上可接受的盐的有效量，以及药学上可接受的载体、辅料或溶剂。
• Development of a New Class of Chiral Phosphorus Ligands:  P-Chirogenic Diaminophosphine Oxides. A Unique Source of Enantioselection in Pd-Catalyzed Asymmetric Construction of Quaternary Carbons
  作者：Tetsuhiro Nemoto、Takamasa Masuda、Takayoshi Matsumoto、Yasumasa Hamada

  DOI：10.1021/jo050800y

  日期：2005.9.1

  phosphorus compounds have been successfully applied to Pd-catalyzed asymmetric construction of tertiary and quaternary carbons. The actual ligand structure was the trivalent phosphorus species 17, which was generated in situ by BSA-induced P(V) to P(III) transformation of 6, the preligand. Detailed mechanistic studies, including asymmetric amplification and initial rate kinetics, revealed that complex 18

  我们最近开发了新的一类手性磷配体：P-手性二氨基膦氧化物。这些五价磷化合物已成功地应用于Pd催化的叔碳和季碳的不对称结构。实际的配体结构是三价磷物质17，它是由BSA诱导的6（前配体）的P（V）到P（III）转化原位生成的。详细的力学研究，包括不对称扩增和初始速率动力学，揭示了复杂的18 [Pd- 17（1：2）络合物]是活性催化剂。还阐明了配体侧臂上氮原子的重要功能。不对称季碳结构中对映体的来源是由N-Zn配位介导的次级配体底物相互作用。

表征谱图